Ups and downs: The STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling

被引：185

作者：

Regis, Gabriella ^{[1
]}

Pensa, Sara ^{[1
]}

Boselli, Daniela ^{[2
,3
]}

Novelli, Francesco ^{[2
,3
]}

Poli, Valeria ^{[1
]}

机构：

[1] Univ Turin, Ctr Mol Biotechnol, I-10126 Turin, Italy

[2] San Giovanni Battista Hosp, CERMS, Turin, Italy

[3] Univ Turin, Dept Med & Expt Oncol, I-10126 Turin, Italy

来源：

SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY | 2008年 / 19卷 / 04期

关键词：

STAT1; STAT3; gp130; cytokines; Interferons; Signalling;

D O I：

10.1016/j.semcdb.2008.06.004

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Downstream of cytokine or growth factor receptors, STAT3 counteracts inflammation and promotes cell survival/proliferation and immune tolerance while STAT1 inhibits proliferation and favours innate and adaptive immune responses. STAT1 and STAT3 activation are reciprocally regulated and perturbation in their balanced expression or phosphorylation levels may re-direct cytokine/growth factor signals from proliferative to apoptotic, or from inflammatory to anti-inflammatory. Here we review the functional canonical and non-canonical effects of STAT1/3 activation and discuss the hypothesis that perturbation of their expression and/or activation levels may provide novel therapeutic strategies in different clinical settings and particularly in cancer. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：351 / 359

页数：9

共 173 条

[1] Cytokines and transcription factors that regulate T helper cell differentiation: New players and new insights [J].

Agnello, D ;

Lankford, CSR ;

Bream, J ;

Morinobu, A ;

Gadina, M ;

O'Shea, JJ ;

Frucht, DM .

JOURNAL OF CLINICAL IMMUNOLOGY, 2003, 23 (03) :147-161

[2] SOCS1 is a critical inhibitor of interferon γ signaling and prevents the potentially fatal neonatal actions of this cytokine [J].

Alexander, WS ;

Starr, R ;

Fenner, JE ;

Scott, GL ;

Handman, E ;

Sprigg, NS ;

Corbin, JE ;

Cornish, AL ;

Darwiche, R ;

Owczarek, CM ;

Kay, TWH ;

Nicola, NA ;

Hertzog, PJ ;

Metcalf, D ;

Hilton, DJ .

CELL, 1999, 98 (05) :597-608

[3]

Allione A, 1999, J IMMUNOL, V163, P4182

[4] Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene activation in the liver [J].

Alonzi, T ;

Maritano, D ;

Gorgoni, B ;

Rizzuto, G ;

Libert, C ;

Poli, V .

MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (05) :1621-1632

[5] Differentiation-dependent expression of signal transducers and activators of transcription (STATs) might modify responses to growth factors in the cancers of the head and neck [J].

Arany, I ;

Chen, SH ;

Megyesi, JK ;

Adler-Storthz, K ;

Chen, Z ;

Rajaraman, S ;

Ember, IA ;

Tyring, SK ;

Brysk, MM .

CANCER LETTERS, 2003, 199 (01) :83-89

[6] A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis [J].

Atsumi, T ;

Ishihara, K ;

Kamimura, D ;

Ikushima, H ;

Ohtani, T ;

Hirota, S ;

Kobayashi, H ;

Park, SJ ;

Saeki, Y ;

Kitamura, Y ;

Hirano, T .

JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (07) :979-990

[7] Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin β6 [J].

Azare, Janeen ;

Leslie, Kenneth ;

Al-Ahmadie, Hikmat ;

Gerald, William ;

Weinreb, Paul H. ;

Violette, Shelia M. ;

Bromberg, Jacqueline .

MOLECULAR AND CELLULAR BIOLOGY, 2007, 27 (12) :4444-4453

[8] Hematopoietic cytokine receptor signaling [J].

Baker, S. J. ;

Rane, S. G. ;

Reddy, E. P. .

ONCOGENE, 2007, 26 (47) :6724-6737

[9] Smoldering and polarized inflammation in the initiation and promotion of malignant disease [J].

Balkwill, F ;

Charles, KA ;

Mantovani, A .

CANCER CELL, 2005, 7 (03) :211-217

[10] Regression of primary hepatocarcinoma in cancer-prone transgenic mice by local interferon-γ delivery is associated with macrophages recruitment and nitric oxide production [J].

Baratin, M ;

Ziol, M ;

Romieu, R ;

Kayibanda, M ;

Gouilleux, F ;

Briand, P ;

Leroy, P ;

Haddada, H ;

Rénia, L ;

Viguier, M ;

Guillet, JG .

CANCER GENE THERAPY, 2001, 8 (03) :193-202

← 1 2 3 4 5 6 7 8 9 10 →